Blog

Sindromul Guillain-Barré

Plasmapheresis for Guillain-Barre Syndrome: Benefits, Risks, and Dose

Patient undergoing plasmapheresis

Considering plasmapheresis for Guillain-Barre syndrome? Get insights into its advantages, side effects, optimal dosage, and associated expenses. 

Discutați cu un specialist despre asistența pentru coplată

(877) 778-0318

Plasmapheresis is one of the two effective treatments for Sindromul Guillain-Barré (GBS), with the other being IVIG [1]. Plasmapheresis can also be called plasma exchange (PE), and it involves the following steps:

  • Withdrawal: Whole blood is removed from a large vein and sent to a special machine. 
  • Separation: The machine separates plasma (the liquid part of the blood) from blood cells. 
  • Replacement: Purified plasma or a plasma replacement fluid (like albumin) with the blood cells is infused back into the bloodstream. 

In addition to GBS, healthcare providers may use plasmapheresis to treat other medical conditions, including:

Plasmapheresis for Guillain-Barre Syndrome: Why Is It Done?

In GBS, the immune system produces proteins called (auto)antibodies that attack the peripheral nerves. Plasmapheresis removes these antibodies from the blood. 

Plasmapheresis works best when it is initiated early, typically within 7 days after the characteristic symptoms appear. However, you can expect the benefits even when you start it up to 4 weeks after the symptoms appear [2].

According to the American Society for Apheresis (ASFA) Guidelines 2019, plasmapheresis [3]:

  • Speeds recovery
  • Reduces time on the ventilator
  • Benefits individuals with both mild and severe disease

Plasmapheresis is also useful in relapses, which occur in up to 5% to 10% of individuals receiving plasmapheresis or IVIG [3]. 

Experts do not recommend combining plasmapheresis and IVIG in sequential order. Also, there is insufficient evidence to support the use of plasmapheresis after IVIG failure.

How Effective Is Plasmapheresis for Guillain-Barre Syndrome?

Plasmapheresis performed over a 10-day period helps filter out autoantibodies and other immune molecules responsible for the symptoms. It may also reduce recovery time by half. 

According to a Cochrane Review, plasmapheresis is generally safe and superior to supportive care alone in adults with GBS [4].  Plasmapheresis-treated participants are more likely to attain full recovery as well. 

It is unknown if plasmapheresis is effective in children younger than 12 and adults who receive treatment 30 days after the symptoms appear. 

Side Effects of Plasmapheresis for Guillain-Barre Syndrome

Nurse with man suffering chest pain from plasmapheresis


Plasmapheresis may cause side effects, such as [5]:

  • Durere abdominală
  • Anxiety
  • Durere în piept
  • Ameţeală
  • Fall in blood pressure (hypotension)
  • Durere de cap
  • Greaţă 
  • Vărsături
  • Allergic reactions to plasma (chills, fever, rash, hives, shortness of breath, and high-pitched sound while breathing)

When you receive albumin as a replacement fluid, you are more likely to experience:

  • Hypotension
  • Greaţă
  • Vărsături

Obțineți asistență financiară

Programați o consultație

Dose of Plasmapheresis for GBS

The American Society for Apheresis (ASFA) Guidelines 2019 recommends exchanging 1 to 1.5 plasma volumes 5 to 6 times over 10 to 14 days [3]. However, additional treatments may be necessary in some people. 
Pentru adulți:

  • 1 plasma volume (PV) equals approximately 40 ml/kg 
  • 1.5 PV equals approximately 60 ml/kg

Plasmapheresis vs. IVIG: Which Is Better?

Both are equally effective in treating GBS, with few exceptions. Guillain-Barre syndrome (GBS) treatment should be tailored on a case-by-case basis. 

Generally, IVIG (0.4 g/kg body weight daily for 5 days) is as effective as plasmapheresis (200–250 ml plasma/kg body weight in 5 sessions). Both have similar risks of side effects [6].

However, IVIG is often preferred because it is easier to access and administer. 

How Much Does Plasmapheresis Cost?

Cost depends on various factors, including:

  • Where you live
  • The facility where the procedure is performed
  • Whether your insurance plan covers the procedure

Ask your insurance provider if your plan covers plasmapheresis for GBS or if you need prior authorization.
 

REFERINȚE:

  1. Leonhard, Sonja E et al. “Diagnosis and management of Guillain-Barré syndrome in ten steps.” Nature reviews. Neurology vol. 15,11 (2019): 671-683. doi:10.1038/s41582-019-0250-9
  2. Raphaël, J C et al. “Plasma exchange for Guillain-Barré syndrome.” The Cochrane database of systematic reviews, 2 (2002): CD001798. doi:10.1002/14651858.CD001798
  3. Schwartz, Joseph, et al. “Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach From the Writing Committee of the American Society for Apheresis: The Eighth Special Issue.” Journal of Clinical Apheresis, vol. 34, no. 3, June 2019, pp. 171–354. https://doi.org/10.1002/jca.21705.
  4. Raphaël, Jean Claude et al. “Plasma exchange for Guillain-Barré syndrome.” The Cochrane database of systematic reviews, 7 CD001798. 11 Jul. 2012, doi:10.1002/14651858.CD001798.pub2
  5. Stoian, Adina, et al. “Therapeutic plasma exchange as a first-choice therapy for axonal Guillain-Barré syndrome: A case-based review of the literature (Review).” Experimental and therapeutic medicine vol. 21,3 (2021): 265. doi:10.3892/etm.2021.9696
  6. Leonhard, Sonja E et al. “Diagnosis and management of Guillain-Barré syndrome in ten steps.” Nature reviews. Neurology vol. 15,11 (2019): 671-683. doi:10.1038/s41582-019-0250-9
Aceste informații nu înlocuiesc sfatul sau tratamentul medical. Discutați cu medicul dumneavoastră sau cu furnizorul de servicii medicale despre afecțiunea dumneavoastră medicală înainte de a începe orice tratament nou. AmeriPharma® Specialty Care nu își asumă nicio răspundere pentru informațiile furnizate sau pentru orice diagnostic sau tratament efectuat ca urmare a acestuia și nici nu este responsabil pentru fiabilitatea conținutului. AmeriPharma® Specialty Care nu operează toate site-urile web/organizațiile enumerate aici și nici nu este responsabil pentru disponibilitatea sau fiabilitatea conținutului acestora. Aceste listări nu implică și nu constituie o aprobare, sponsorizare sau recomandare din partea AmeriPharma® Specialty Care. Această pagină web poate conține referințe la medicamente eliberate pe bază de rețetă, care sunt mărci comerciale sau mărci comerciale înregistrate ale producătorilor farmaceutici care nu sunt afiliați cu AmeriPharma® Specialty Care.
REVIZUIT MEDICAL DE Dr. Saba Rassouli, doctor în farmacii

Dr. Saba Rassouli, medic specialist în farmacie, s-a născut și a crescut în Iran. Și-a luat diploma de farmacie de la Universitatea Marshall B. Ketchum în 2022, absolvind cu distincție cum laude. Cea mai satisfăcătoare parte a slujbei sale este oportunitatea de a îngriji fiecare pacient ca și cum ar fi membri ai familiei și de a auzi despre cât de fericiți și mulțumiți sunt de serviciile oferite de AmeriPharma. În timpul liber, îi place să meargă la plimbare, să citească cărți și să încerce diferite restaurante și mâncăruri.

Contactaţi-ne

Folosiți formularul conform HIPAA de mai jos pentru a solicita o reînnoire a rețetei dumneavoastră. Dacă aveți întrebări despre medicamentul dumneavoastră sau despre cum să îl administrați, vă rugăm să vizitați pagina Contactați-ne sau să ne sunați la (877) 778-0318.

HIPAA Compliant

Prin trimitere, sunteți de acord cu AmeriPharma Termeni de utilizare, Politica de confidențialitateși Notificare privind practicile de confidențialitate

ro_RORomanian